IP Library Granted Patent US 11,850,278
Granted Patent B2
US 11,850,278 · App. 17/374,424 · Granted Dec 26, 2023

Compositions comprising

Inventors: William J. Smith (Harleysville, PA); Patrick McHugh (Pipersville, PA); Michael A. Winters (Doylestown, PA); Julie M. Skinner (Phoenixville, PA); Jian He (Blue Bell, PA); Luwy Musey (Blue Bell, PA); Chitrananda Abeygunawardana (Ambler, PA); Yadong Adam Cui (Norristown, PA); Michael J. Kosinski (Souderton, PA)
Assignee: Merck Sharp & Dohme LLC
A61K39/092A61K39/116A61K39/145A61K39/385A61K47/02A61K47/10A61K47/22A61P31/04A61K9/0019A61K2039/54A61K2039/545A61K2039/55A61K2039/55516A61K2039/6037A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,850,278
App. No.
17/374,424
Granted
Dec 26, 2023
Kind
B2
Abstract

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae . The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Claims (2)

1. A method for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) in patients comprising administering a multivalent immunogenic composition to the patient, wherein the multivalent immunogenic composition comprises S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes consist of 3, 7F, 19A, 22F, 33F, 6A, 15A, 16F, 23A, 23B, 24F, 31, 35B, 8, 9N, 10A, 11A, 12F, de-O-acetylated 15B, 17F, and 20A, and the carrier protein is CRM197.

2. The method of claim 1 , wherein the de-O-acetylated 15B polysaccharide has an O-Acetyl content per repeating unit of less than 5%.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: SMITH, WILLIAM J.; MCHUGH, PATRICK; WINTERS, MICHAEL A.; SKINNER, JULIE M.; HE, JIAN; MUSEY, LUWY; ABEYGUNAWARDANA, CHITRANANDA; CUI, YADONG ADAM; KOSINSKI, MICHAEL J.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 065511/0797 →
MERGER Recorded Nov 9, 2023
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 065511/0872 →
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2021
From: SMITH, WILLIAM J.; MCHUGH, PATRICK; WINTERS, MICHAEL ALBERT; SKINNER, JULIE M.; HE, JIAN; MUSEY, LUWY; ABEYGUNAWARDANA, CHITRANANDA; CUI, YADONG ADAM; KOSINSKI, MICHAEL J.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 056840/0033 →
Cited By (1)
US 12,257,295